Preface
Introduction: moving beyond chemotherapy
Translational Cancer Research
2015;
4
(1)
:1-2
.
(13 February 2015)
Review Article
Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications
Translational Cancer Research
2015;
4
(1)
:3-13
.
(13 February 2015)
The promise and challenge of ovarian cancer models
Translational Cancer Research
2015;
4
(1)
:14-28
.
(13 February 2015)
Molecular targeting of low-grade serous and mucinous carcinomas of the ovary or peritoneum
Translational Cancer Research
2015;
4
(1)
:29-39
.
(13 February 2015)
Therapeutic implications for ovarian cancer emerging from the Tumor Cancer Genome Atlas
Translational Cancer Research
2015;
4
(1)
:40-59
.
(13 February 2015)
Modulation of intraperitoneal (IP) chemotherapy in ovarian cancer
Translational Cancer Research
2015;
4
(1)
:60-69
.
(13 February 2015)
Targeting angiogenesis: vascular endothelial growth factor and related signaling pathways
Translational Cancer Research
2015;
4
(1)
:70-83
.
(13 February 2015)
Targeting DNA repair: poly (ADP-ribose) polymerase inhibitors
Translational Cancer Research
2015;
4
(1)
:84-96
.
(13 February 2015)
Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
Translational Cancer Research
2015;
4
(1)
:97-106
.
(13 February 2015)
EGFR and HER2: is there a role in ovarian cancer?
Translational Cancer Research
2015;
4
(1)
:107-117
.
(13 February 2015)
Targeting the folate receptor for the treatment of ovarian cancer
Translational Cancer Research
2015;
4
(1)
:118-126
.
(13 February 2015)
Integrating targeted drugs with taxanes and platinums: opportunities and challenges
Translational Cancer Research
2015;
4
(1)
:127-136
.
(13 February 2015)
Disclosure:
The focused issue “Epithelial ovarian cancer treatment: integrating molecular targeting” was commissioned by the editorial office, Translational Cancer Research without any sponsorship or funding. Franco Muggia and Eleonora Teplinsky served as the unpaid Guest Editors for the focused issue.
